Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 12-Month Low Following Analyst Downgrade

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s stock price hit a new 52-week low during trading on Friday after Wells Fargo & Company lowered their price target on the stock from $1,050.00 to $900.00. Wells Fargo & Company currently has an overweight rating on the stock. Regeneron Pharmaceuticals traded as low as $691.00 and last traded at $698.34, with a volume of 492017 shares traded. The stock had previously closed at $733.59.

Several other research firms have also weighed in on REGN. Citigroup assumed coverage on Regeneron Pharmaceuticals in a report on Thursday, November 14th. They issued a “neutral” rating and a $895.00 target price on the stock. Morgan Stanley dropped their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday. BMO Capital Markets cut their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Finally, Evercore ISI lowered their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,037.33.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Mizuho Securities USA LLC boosted its position in shares of Regeneron Pharmaceuticals by 625.5% in the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock worth $62,382,000 after buying an additional 51,162 shares during the period. Tri Locum Partners LP boosted its holdings in Regeneron Pharmaceuticals by 104.5% in the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock worth $18,410,000 after acquiring an additional 8,949 shares during the period. Principal Financial Group Inc. grew its position in Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after acquiring an additional 2,828 shares in the last quarter. Simplify Asset Management Inc. raised its stake in shares of Regeneron Pharmaceuticals by 50.8% during the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock valued at $10,082,000 after purchasing an additional 3,231 shares during the period. Finally, Catalytic Wealth RIA LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth $1,334,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 4.9 %

The firm has a market capitalization of $76.70 billion, a PE ratio of 17.27, a P/E/G ratio of 2.19 and a beta of 0.10. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm’s 50 day moving average price is $754.37 and its two-hundred day moving average price is $965.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.